Mupirocin

Mupirocin, also known as Pseudomonas A, is an ideal anti-bacterial preparation for the skin surface and was marketed by GlaxoSmithKline in 1985 under the brand name Bactroban. The FDA approved Chemicalbook for use in the United States in 1987, and China approved MidAmerican SmithKline Pharmaceutical to manufacture and sell the drug in 1993. Mupiroxacin is used to prevent and treat bacterial skin infections caused by Gram-positive bacteria. Mupirocin is mainly used for the prevention and treatment of bacterial skin infections caused by Gram-positive coccus, such as impetigo, furuncle, folliculitis and other primary skin infections, and eczema Chemicalbook co-infection, ulcer co-infection, trauma co-infection and other secondary skin infections. The main mechanism of mupirocin's antibacterial action is the inhibition of protein synthesis in bacteria